Cargando…

Evaluation of RNA-binding motif protein 3 expression in urothelial carcinoma of the bladder: an immunohistochemical study

BACKGROUND: RNA-binding motif protein 3 (RBM3), involved in cell survival, has paradoxically been linked to both oncogenesis as well as an increased survival in several cancers, including urothelial carcinoma (UCA). METHODS: The putative prognostic role of RBM3 was studied using cystectomy specimens...

Descripción completa

Detalles Bibliográficos
Autores principales:	Florianova, Livia, Xu, Bin, Traboulsi, Samer, Elmansi, Hazem, Tanguay, Simon, Aprikian, Armen, Kassouf, Wassim, Brimo, Fadi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4650614/ https://www.ncbi.nlm.nih.gov/pubmed/26577765 http://dx.doi.org/10.1186/s12957-015-0730-3

Ejemplares similares

Changes in the outcome of prostate biopsies after preventive task force recommendation against prostate-specific antigen screening
por: Zakaria, Ahmed S., et al.
Publicado: (2018)

Aldehyde dehydrogenase 1 expression in primary and metastatic renal cell carcinoma: an immunohistochemistry study
por: Abourbih, Samuel, et al.
Publicado: (2013)

Retroperitoneal lymph node dissection for residual masses after chemotherapy in nonseminomatous germ cell testicular tumor
por: Luz, Murilo A, et al.
Publicado: (2010)

Phase I Clinical Trial of Everolimus Combined with Trimodality Therapy in Patients with Muscle-Invasive Bladder Cancer
por: Bachir, Bassel G., et al.
Publicado: (2017)

Improving ultrasound-based prostate volume estimation
por: Aprikian, Saro, et al.
Publicado: (2019)

Role of Serum Lymphocyte-derived Biomarkers in Nonmetastatic Muscle-invasive Bladder Cancer Patients Treated with Trimodal Therapy
por: Kool, Ronald, et al.
Publicado: (2021)

Chronic prednisone, metformin, and nonsteroidal anti-inflammatory drug use and clinical outcome in a cohort of bladder cancer patients undergoing radical cystectomy in Québec, Canada
por: Wissing, Michel D., et al.
Publicado: (2023)

Plasmacytoid urothelial carcinoma of the bladder: a case report
por: Aldousari, Saad, et al.
Publicado: (2009)

Health-care services utilization and costs associated with radical cystectomy for bladder cancer: a descriptive population-based study in the province of Quebec, Canada
por: Santos, Fabiano, et al.
Publicado: (2015)

Feasibility and Impact of Immunohistochemistry-based Molecular Subtyping for Muscle-invasive Bladder Cancer in Patients Treated with Radiation-based Therapy
por: Hesswani, Charles, et al.
Publicado: (2023)

PTEN genomic deletion predicts prostate cancer recurrence and is associated with low AR expression and transcriptional activity
por: Choucair, Khalil, et al.
Publicado: (2012)

Role of neutrophil extracellular traps in radiation resistance of invasive bladder cancer
por: Shinde-Jadhav, Surashri, et al.
Publicado: (2021)

Impact of Programmed Death-ligand 1 Expression on Oncological Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Radiation-based Therapy
por: Marcq, Gautier, et al.
Publicado: (2022)

Combined radiotherapy and immunotherapy in urothelial bladder cancer: harnessing the full potential of the anti-tumor immune response
por: Daro-Faye, Mame, et al.
Publicado: (2020)

Bladder-sparing protocols in the treatment of muscle-invasive bladder cancer
por: Tholomier, Côme, et al.
Publicado: (2020)

Relationship between initial PSA density with future PSA kinetics and repeat biopsies in men with prostate cancer on active surveillance
por: Kotb, A F, et al.
Publicado: (2011)

Early detection of clinically significant prostate cancer at diagnosis: a prospective study using a novel panel of TMPRSS2:ETS fusion gene markers
por: Chan, Sam W., et al.
Publicado: (2013)

Cell‐by‐cell quantification of the androgen receptor in benign and malignant prostate leads to a better understanding of changes linked to cancer initiation and progression
por: Derderian, Seta, et al.
Publicado: (2023)

Radical Cystectomy is the best choice for most patients with muscle-invasive bladder cancer? Opinion: Yes
por: Monteiro, Leonardo L., et al.
Publicado: (2017)

Decreased expression of RNA-binding motif protein 3 correlates with tumour progression and poor prognosis in urothelial bladder cancer
por: Boman, Karolina, et al.
Publicado: (2013)

Podocalyxin-like and RNA-binding motif protein 3 are prognostic biomarkers in urothelial bladder cancer: a validatory study
por: Boman, Karolina, et al.
Publicado: (2017)

Immunohistochemical and molecular characterizations in urothelial carcinoma of bladder in patients less than 45 years
por: Weyerer, Veronika, et al.
Publicado: (2017)

Presence of lymphocytic infiltrate cytotoxic T lymphocyte CD3(+), CD8(+), and immunoscore as prognostic marker in patients after radical cystectomy
por: Yu, Alice, et al.
Publicado: (2018)

Comprehensive Gene Expression Analyses of Immunohistochemically Defined Subgroups of Muscle-Invasive Urinary Bladder Urothelial Carcinoma
por: Kim, Bohyun, et al.
Publicado: (2021)

Immunohistochemical expression of TROP‑2 (TACSTD2) on the urothelial carcinoma of the urinary bladder and other types of cancer
por: Abbas, Mahmoud, et al.
Publicado: (2023)

Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma
por: D’Andrea, David, et al.
Publicado: (2020)

Erectile function after partial penectomy for penile cancer
por: Monteiro, Leonardo L., et al.
Publicado: (2020)

Renal Angiomyxolipoma: Its First Appearance!()
por: Traboulsi, Samer L., et al.
Publicado: (2014)

Combined use of immunohistochemical markers of basal and luminal subtypes in urothelial carcinoma of the bladder: Association with clinicopathological features and outcomes
por: Ravanini, Juliana Naves, et al.
Publicado: (2021)

A Sarcomatoid Renal Cell Carcinoma with Clear Cell Papillary-Like Primary Tumor and Lymph Node Metastasis: A Diagnostic Conundrum
por: Demko, Nadine, et al.
Publicado: (2022)

Triple‐marker immunohistochemical assessment of muscle‐invasive bladder cancer: Is there prognostic significance?
por: Labban, Muhieddine, et al.
Publicado: (2021)

Prognostic Value of c-Myc Immunohistochemical Expression in Muscle Invasive Urothelial Carcinoma of the Urinary Bladder: A Retrospective Study
por: Elwy, Amira Emad, et al.
Publicado: (2019)

Combining mTOR Inhibition with Radiation Improves Antitumor Activity in Bladder Cancer Cells In Vitro and In Vivo: A Novel Strategy for Treatment
por: Nassim, Roland, et al.
Publicado: (2013)

Asporin is a stromally expressed marker associated with prostate cancer progression
por: Rochette, Annie, et al.
Publicado: (2017)

Comparison of three validated PD-L1 immunohistochemical assays in urothelial carcinoma of the bladder: interchangeability and issues related to patient selection
por: Munari, Enrico, et al.
Publicado: (2022)

Differential Immunohistochemical Profiles for Distinguishing Prostate Carcinoma and Urothelial Carcinoma
por: Oh, Woo Jin, et al.
Publicado: (2016)

Evidence for Bladder Urothelial Pathophysiology in Functional Bladder Disorders
por: Keay, Susan K., et al.
Publicado: (2014)

Gelsolin, an Actin-Binding Protein: Bioinformatic Analysis and Functional Significance in Urothelial Bladder Carcinoma
por: Alsofyani, Abeer A., et al.
Publicado: (2023)

Immunohistochemical analysis of chromatin remodeler DAXX in high grade urothelial carcinoma
por: Zizzi, Antonio, et al.
Publicado: (2013)

A Novel Mechanism of PPAR Gamma Induction via EGFR Signalling Constitutes Rational for Combination Therapy in Bladder Cancer
por: Mansure, Jose Joao, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_1klqiq48s4jb5aquche1s8h8q5